Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 101, Issue 12, Pages 5012-5020Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.2016-2869
Keywords
-
Categories
Funding
- Arthritis Research UK [17702]
- Medical Research Council [4050502589, U105960371]
- Bupa Foundation
- National Institute for Health Research (NIHR) Southampton Biomedical Research Centre
- University of Southampton
- University Hospital Southampton National Health Service (NHS) Foundation Trust
- NIHR Musculoskeletal Biomedical Research Unit, University of Oxford
- European Union's Seventh Framework Programme (FP7) [289346, 613977]
- Medical Research Council [MC_UU_12011/4, MR/K006312/1, MC_U147585824, MC_U147585827, G0400491, MC_U147585819, U1475000001, MC_U105960371, MC_UU_12011/2, MC_UU_12011/1, U1475000002, MC_UP_A620_1014, MC_UP_A620_1017] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10082, NF-SI-0513-10085, 10/33/04, NF-SI-0515-10042] Funding Source: researchfish
- Royal Osteoporosis Society [366] Funding Source: researchfish
- Versus Arthritis [19583, 21231, 17702] Funding Source: researchfish
- MRC [MC_U147585827, MC_UP_A620_1017, MC_UU_12011/2, MC_UU_12011/4, G0400491, MC_U105960371, MC_U147585819, MR/K006312/1] Funding Source: UKRI
Ask authors/readers for more resources
Context: individual differences in 25-hydroxyvitamin D (25(OH) D) response. Objective: We assessed which maternal and environmental characteristics were associated with 25(OH) D after supplementation with cholecalciferol. Design: Within-randomization-group analysis of participants in the Maternal Vitamin D Osteoporosis Study trial of vitamin D supplementation in pregnancy. Setting: Hospital antenatal clinics. Participants: Atotal of 829 pregnantwomen(422 placebo, 407 cholecalciferol). At 14 and 34 weeks of gestation, maternal anthropometry, health, and lifestyle were assessed and 25(OH) D measured. Compliance was determined using pill counts at 19 and 34 weeks. Interventions: 1000 IU/d of cholecalciferol or matched placebo from 14 weeks of gestation until delivery. Main Outcome Measure: 25(OH) D at 34 weeks, measured in a single batch (Diasorin Liaison). Results: 25(OH) D at 34 weeks of gestation was higher in the women randomized to vitamin D (mean [SD], 67.7 [21.3] nmol/L) compared with placebo (43.1 [22.5] nmol/L; P < .001). In women randomized to cholecalciferol, higher pregnancy weight gain from 14 to 34 weeks of gestation (kg) (beta = -0.81 [ 95% confidence interval -1.39, -0.22]), lower compliance with study medication (%) (beta = -0.28 [-0.072, -0.48]), lower early pregnancy 25(OH) D (nmol/L) (beta = 0.28 [0.16, 0.40]), and delivery in the winter vs the summer (beta = -10.5 [-6.4, -14.6]) were independently associated with lower 25(OH) D at 34 weeks of gestation. Conclusions: Women who gained more weight during pregnancy had lower 25(OH) D in early pregnancy and delivered in winter achieved a lower 25(OH) D in late pregnancy when supplemented with 1000 IU/d cholecalciferol. Future studies should aim to determine appropriate doses to enable consistent repletion of 25(OH) D during pregnancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available